NY-SOLIDUS-LABS/FTX
3.5.2022 14:02:30 CEST | Business Wire | Press release
FTX Digital Markets (“FTX”), the Bahamian subsidiary of FTX Trading Ltd., today announced that it has partnered with Solidus Labs, a category-definer for crypto risk monitoring, to provide market surveillance and transaction monitoring across FTX’s platform. As part of the partnership, FTX will deploy Solidus’ HALO platform, which provides risk monitoring, fraud-prevention and compliance services for digital assets.
“FTX Digital Markets has always been committed to providing our users with industry-leading products and services, while also promoting full transparency and holding ourselves to the standards commonly found in legacy finance,” said Ryan Salame, Co-CEO of FTX Digital Markets. “Solidus’ crypto-native approach, commitment to enabling transparency within the crypto ecosystem, and tools tailored for digital asset trade monitoring and surveillance makes the partnership an obvious choice. We are looking forward to working with the Solidus team to position our users for success by providing market-leading regulatory, compliance and security services.”
Solidus HALO is currently used to monitor more than 1 trillion events per day across more than 150 markets, protecting more than 25 million retail and institutional entities. It will enable FTX to access risk and compliance programs in one platform, while also utilizing behavioral-based detection models powered by machine-learning to address a range of crypto-specific threats and alerts. Advanced investigative tools, case management capabilities, 24/7 real-time monitoring and more than 200 integration points supported by HALO will provide FTX with insight into market integrity and allow it to identify potential risks across on-chain and off-chain data. The platform also amplifies FTX’s compliance capabilities amidst an evolving regulatory landscape.
“FTX is leading the charge towards safer crypto markets, driving public and institutional adoption, and taking the industry forward,” added Asaf Meir, Solidus Labs’ Founder and Chief Executive. “We’re delighted to support their effort through our crypto-native tools, and to continue working together to enable the potential of crypto to make finance more accessible, transparent and efficient, by mitigating the new risks.”
FTX Digital Markets
FTX Digital Markets is the Bahamian subsidiary of FTX Trading Ltd., owner and operator of FTX, a leading cryptocurrency exchange built by traders for traders. FTX Digital Markets offers users regulated access to FTX's industry-leading derivatives, options, volatility products, as well as other FTX products and services. To learn more, please visit: https://ftx.com/
Solidus Labs
Solidus Labs is the category-definer for crypto-native triple T (T3) market integrity solutions - trade surveillance, transaction monitoring, and threat intelligence. Our mission is to enable safe crypto trading throughout the investment journey across all centralized and DeFi markets. As the founder of industry leading initiatives like the Crypto Market Integrity Coalition and DACOM Summit , and in everything we do, Solidus is deeply committed to ushering in the financial markets of tomorrow. To learn more, please visit: https://soliduslabs.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005469/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom